Institution
Clinical Emergency Hospital Bucharest
Healthcare•Bucharest, Romania•
About: Clinical Emergency Hospital Bucharest is a healthcare organization based out in Bucharest, Romania. It is known for research contribution in the topics: Population & Medicine. The organization has 381 authors who have published 276 publications receiving 2188 citations. The organization is also known as: Floreasca Hospital & Spitalul Floreasca.
Topics: Population, Medicine, Cancer, Type 2 diabetes, Cirrhosis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Hypertensive ACS patients in Romania represent a higher risk group, since they are more often discharged with NYHA class ≥ III, are older and have an adverse clinical profile, and in the elderly, the outcomes of the hypertensive patients are worse than non-hypertensive patients.
Abstract: There is little information on the incidence and prognostic significance of arterial hypertension (HTN) in acute coronary syndromes (ACSs), especially in the east European countries. We sought to investigate a registry of ACS patients in Romania, in order to better elucidate whether hypertensive patients are at higher risk of death and deserve a tailored approach for management and follow-up. The data of this study are a framework of the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) (ClinicalTrials.gov, [NCT01218776][1]). The present analysis focused on 2286 retrospective patients admitted to 23 hospitals in Romania with a diagnosis of ACS. Among 1450 hypertensive patients, 64.5% were admitted with a diagnosis of ST elevation myocardial infarction (STEMI), while the remaining was admitted with a diagnosis of non-STEMI (NSTEMI). When compared with non-hypertensive patients, hypertensive patients were older (mean age 60.3 vs. 66.7 years, P 65 years) patients with both STEMI and NSTEMI. Hypertensive ACS patients in Romania represent a higher risk group, since they are more often discharged with NYHA class ≥ III, are older and have an adverse clinical profile. In the elderly, the outcomes of the hypertensive patients are worse than non-hypertensive patients.
[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01218776&atom=%2Fehjsupp%2F16%2Fsuppl_A%2FA20.atom
13 citations
••
TL;DR: It is suggested that subclinical hypothyroidism can lead to coagulation disorders and deep venous thrombosis which can explain some cases of sudden death associated with pulmonary embolism without other significant risk factors.
13 citations
••
Rio de Janeiro State University1, Vilnius University2, University of Nantes3, French Institute of Health and Medical Research4, Federal Almazov North-West Medical Research Centre5, University College London6, University of Pisa7, University of Yaoundé8, University of the Philippines9, Clinical Emergency Hospital Bucharest10, Carol Davila University of Medicine and Pharmacy11, Cardiovascular Institute of the South12, Comenius University in Bratislava13, Gdańsk Medical University14, Saint Petersburg State University of Information Technologies, Mechanics and Optics15, University of Paris16
TL;DR: The barriers to the uptake of the first-line prescription of two antihypertensive drugs in single-pill combinations (SPCs), also known as fixed-dose combinations, are discussed.
Abstract: The 2008 European Society of Cardiology/European Society of Hypertension guidelines recommend the first-line prescription of two antihypertensive drugs in single-pill combinations (SPCs), also known as fixed-dose combinations, for the treatment of most patients with hypertension. This recommendation is based on a large amount of data, which shows that first-line treatment with SPCs supports reaching blood pressure targets rapidly and reducing cardiovascular outcome risk while keeping the therapeutic strategies as simple as possible and fostering adherence and persistence. As this approach constitutes a big shift from the stepped-care approaches that have been dominant for many years, practicing physicians have expressed concerns about using SPCs as first-line agents. In this review, we will discuss the barriers to the uptake of this recommendation. We will also offer suggestions to reduce the impact of these barriers and address specific concerns that have been raised.
13 citations
••
TL;DR: Continuous screening consists of annual clinical, biochemical, and ultrasound assessments in asymptomatic patients and annual colonoscopy in patients with PSC and inflammatory bowel disease and further studies are in progress to establish the effect of molecular-targeted therapies in PSC.
Abstract: Primary sclerosing cholangitis is a progressive liver disease characterized by chronic inflammation leading to liver fibrosis and cirrhosis. Even though the exact pathogenesis is still unclear, a combination of autoimmune, environmental, and ischemic factors could explain certain aspects of the disease. The most important diagnostic step is cholangiography, which can be obtained either by endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiography (MRCP as the gold standard), or percutaneous transhepatic cholangiography. It shows multifocal short biliary duct strictures leading to the “beaded” aspect. Cholangiocarcinoma and colorectal adenocarcinoma are the most feared complications in patients with Primary sclerosing cholangitis (PSC). Continuous screening consists of annual clinical, biochemical, and ultrasound assessments in asymptomatic patients and annual colonoscopy in patients with PSC and inflammatory bowel disease. In newly diagnosed patients with PSC, colonoscopy is mandatory and, if negative, then, a repeat colonoscopy should be performed in 3–5 years. The lack of efficient curative medical treatment makes invasive treatments such as liver transplant and endoscopy the mainstream for managing PSC and its complications. Until now, even though only ursodeoxycholic acid has shown a moderate clinical, biochemical, and even histological improvement, it has no significant influence on the risk of cholangiocarcinoma, liver transplant need, or death risk and it is no longer recommended in treating early PSC. Further studies are in progress to establish the effect of molecular-targeted therapies in PSC.
13 citations
••
Clinical Emergency Hospital Bucharest1, University of Bologna2, University of Belgrade3, Saints Cyril and Methodius University of Skopje4, Lithuanian University of Health Sciences5, University of Zagreb6, University of Sarajevo7, Autonomous University of Barcelona8, Carol Davila University of Medicine and Pharmacy9
TL;DR: Sex, comorbidities, and late hospital admission were independent factors associated with the underuse of PCI in patients over 75, and older age was associated with underuse in these patients.
13 citations
Authors
Showing all 397 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bogdan A. Popescu | 65 | 284 | 69502 |
Ionut Negoi | 43 | 168 | 29046 |
Mihaela Hostiuc | 21 | 45 | 11644 |
Maria Dorobantu | 15 | 57 | 634 |
Camelia Cristina Diaconu | 15 | 185 | 990 |
Ioan Lascar | 14 | 83 | 484 |
Razvan Multescu | 13 | 68 | 674 |
Daniela Bartos | 12 | 57 | 1755 |
Cristian Balalau | 12 | 86 | 405 |
Bogdan Socea | 11 | 138 | 557 |
Gelu Onose | 11 | 61 | 706 |
Valentin Titus Grigorean | 10 | 40 | 467 |
Elisabeta Badila | 10 | 38 | 432 |
Octav Ginghina | 10 | 27 | 252 |
O. Tautu | 9 | 13 | 3109 |